Evidence map›Paper›PMID 40573334›Full record

ArticleViruses2025

Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia.

Amgalan Byambasuren, Buyankhishig Gyarvuulkhasuren, Byambatsogt Erdenebat, Khurelbaatar Nyamdavaa, Oidov Baatarkhuu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amgalan ByambasurenDepartment of Health Research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Buyankhishig GyarvuulkhasurenGeneral Hospital of the Arkhangai Province, Tsetserleg 65191, Mongolia.
Byambatsogt ErdenebatHealth Department of the Arkhangai Province, Tsetserleg 65089, Mongolia.
Khurelbaatar NyamdavaaDepartment of Physiology, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Oidov BaatarkhuuDepartment of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.ORCID 0000-0002-0769-3693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Hepatitis C virus (HCV) infection poses a significant health burden, particularly in Mongolia, where the HCV prevalence is notably high. This study evaluates the long-term outcomes of HCV treatment with ledipasvir/sofosbuvir, focusing on mortality, viral relapse, and hepatocellular carcinoma (HCC) development. (2) Methods: This prospective, longitudinal cohort study initially enrolled patients with chronic HCV in Mongolia between 2016 and 2017, focusing on those who completed the five-year follow-up (

Indexed as

Antiviral AgentsBenzimidazolesCarcinoma, HepatocellularFluorenesHepatitis C, ChronicLiver NeoplasmsSofosbuvirAdultAgedFemaleHepacivirusHumansLiver CirrhosisLongitudinal StudiesMaleMiddle AgedAntiviral AgentsBenzimidazolesFluorenesledipasvir, sofosbuvir drug combinationSofosbuvirantiviral therapychronic liver diseaseliver cirrhosisviral suppression

Identifiers

PMID40573334
PMCPMC12197668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.